The Autosomal Dominant Hypocalcemia Type 1 Market Size is predicted to grow at a 2.96% CAGR during the forecast period for 2024-2031. Autosomal dominant hypocalcemia type 1 (ADH1) is a rare inherited condition characterized by abnormally low blood calcium levels. This condition is caused by mutations in the CASR gene, which produces the calcium-sensing receptor protein. The calcium-sensing receptor is involved in blood calcium homeostasis regu...
Report ID: 2894 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 165
The Diabetic Macular Edema Market Size is valued at USD 3.95 billion in 2023 and is predicted to reach USD 4.56 billion by the year 2031 at a 1.9% CAGR during the forecast period for 2024-2031. Diabetic Macular Edema (DME) is an ocular disorder associated with diabetes, characterized by fluid accumulation in the macula, resulting in swelling and impaired central vision. If untreated, it may result in visual loss; however, therapy alternatives ...
Report ID: 2895 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 167
The Cytokine Release Syndrome Management Market Size is valued at USD 23.1 billion in 2023 and is predicted to reach USD 36.8 billion by the year 2031 at a 6.2% CAGR during the forecast period for 2024-2031. Management of Cytokine Release Syndrome (CRS) entails regulating a severe immune response that may arise during treatments such as CAR T-cell therapy. Hence, the adoption of Cytokine Release Syndrome Management is expected to increase in t...
Report ID: 2896 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 170
The Mitochondrial-Based Therapeutics Market Size is valued at USD 388.2 Mn in 2023 and is predicted to reach USD 682.7 Mn by the year 2031 at a 7.5% CAGR during the forecast period for 2024-2031. Mitochondrial-based therapeutics focus on the fundamental causes of mitochondrial failure, representing a novel approach to treating a variety of illnesses and conditions. Hence, the adoption of Mitochondrial-Based Therapeutics is expected to increase...
Report ID: 2884 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 172
The Idiopathic Pulmonary Fibrosis Management Market Size is valued at USD 3,113.5 Mn in 2023 and is predicted to reach USD 3,429.6 Mn by the year 2031 at a 1.28% CAGR during the forecast period for 2024-2031. Idiopathic Pulmonary Fibrosis Management is referred to as a serious disease related to the lungs, which stiffens, thickens, and damages the lung tissues over a prolonged period. Hence, the adoption of idiopathic pulmonary fibrosis manage...
Report ID: 2885 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 165
The Immune-Mediated Inflammatory Diseases Market Size is estimated to grow at a 7.10% CAGR during the forecast period for 2024-2031. Immune-mediated inflammatory disease (IMID) is refered as a collection of unrelated illnesses that have a common inflammatory pathway that causes inflammation but no clear etiology. Immune-mediated inflammatory diseases are disorders brought on by the immune system's excessive or aberrant activity. All immune-med...
Report ID: 2889 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 165
The Global Softwall Cleanrooms Market Size is predicted to record at a 5.24% CAGR during the forecast period for 2023-2031. Manufacturing requirements for semiconductors, medical devices, and other products are cleaned in softwall cleanrooms. The need for cleanrooms rises as a result of the control they offer over environmental factors like temperature and the possibility of particle entry. A regulated environment where product contamination i...
Report ID: 1784 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 180
The Sprycel Market Size is valued at USD 5.47 Bn in 2022 and is predicted to reach USD 8.52 Bn by the year 2031 at a 5.2% CAGR during the forecast period for 2023-2031. One of the effective cancer drugs is Sprycel. Adults with some significant forms of leukaemia (cancer of the white blood cells) are treated with it. Adult patients should use SPRYCEL® (dasatinib) for therapy. Newly discovered chronic myeloid leukaemia (CML) in the chronic p...
Report ID: 2041 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 180
The Clinical Trial Biorepository & Archiving Solutions Market Size is valued at USD 4.24 Bn in 2023 and is predicted to reach USD 8.49 Bn by the year 2031 at an 9.12% CAGR during the forecast period for 2024-2031. Clinical trial biorepositories and archiving solutions play pivotal roles in the pharmaceutical and biomedical research sectors by providing specialized facilities and ...
Report ID: 2553 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 180
Global CIN And HR-HPV Treatment Market Size is valued at USD 11.48 billion in 2022 and is predicted to reach USD 20.08 billion by the year 2031 at a 6.5% CAGR during the forecast period for 2023-2031. CIN and HR-HPV treatment Cervical infection with human papillomavirus type 16 (HR-HPV 16) is a key risk factor for cervical intraepithelial neoplasia and a sexually transmitted disease. The most significant cause of cervical cancer is the human p...
Report ID: 2044 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 180
Pharmaceuticals